Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Rheumatoid Arthritis

  Free Subscription


Articles published in Arthritis Res Ther

Retrieve available abstracts of 134 articles:
HTML format
Text format



Single Articles


    October 2018
  1. TEITSMA XM, Yang W, Jacobs JWG, Petho-Schramm A, et al
    Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology.
    Arthritis Res Ther. 2018;20:230.
    PubMed     Text format     Abstract available


  2. DAVIGNON JL, Rauwel B, Degboe Y, Constantin A, et al
    Modulation of T-cell responses by anti-tumor necrosis factor treatments in rheumatoid arthritis: a review.
    Arthritis Res Ther. 2018;20:229.
    PubMed     Text format     Abstract available


  3. WANG S, Wang L, Wu C, Sun S, et al
    E2F2 directly regulates the STAT1 and PI3K/AKT/NF-kappaB pathways to exacerbate the inflammatory phenotype in rheumatoid arthritis synovial fibroblasts and mouse embryonic fibroblasts.
    Arthritis Res Ther. 2018;20:225.
    PubMed     Text format     Abstract available


  4. TERSLEV L, Ostergaard M, Sexton J, Hammer HB, et al
    Is synovial hypertrophy without Doppler activity sensitive to change? Post-hoc analysis from a rheumatoid arthritis ultrasound study.
    Arthritis Res Ther. 2018;20:224.
    PubMed     Text format     Abstract available


  5. ZHANG LM, Zhou JJ, Luo CL
    CYLD suppression enhances the pro-inflammatory effects and hyperproliferation of rheumatoid arthritis fibroblast-like synoviocytes by enhancing NF-kappaB activation.
    Arthritis Res Ther. 2018;20:219.
    PubMed     Text format     Abstract available


    September 2018
  6. SZEREMETA A, Jura-Poltorak A, Kozma EM, Glowacki A, et al
    Effects of a 15-month anti-TNF-alpha treatment on plasma levels of glycosaminoglycans in women with rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:211.
    PubMed     Text format     Abstract available


    August 2018
  7. THAI TN, Dawwas GK
    Comments on the article "Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study".
    Arthritis Res Ther. 2018;20:198.
    PubMed     Text format    


  8. NIU Q, Huang ZC, Wu XJ, Jin YX, et al
    Enhanced IL-6/phosphorylated STAT3 signaling is related to the imbalance of circulating T follicular helper/T follicular regulatory cells in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:200.
    PubMed     Text format     Abstract available


  9. IWAMOTO N, Fukui S, Takatani A, Shimizu T, et al
    Osteogenic differentiation of fibroblast-like synovial cells in rheumatoid arthritis is induced by microRNA-218 through a ROBO/Slit pathway.
    Arthritis Res Ther. 2018;20:189.
    PubMed     Text format     Abstract available


  10. FLEISCHMANN RM, Alten R, Pileckyte M, Lobello K, et al
    A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira(R)) in the treatment of active rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:178.
    PubMed     Text format     Abstract available


  11. JOHANSSON K, Askling J, Alfredsson L, Di Giuseppe D, et al
    Mediterranean diet and risk of rheumatoid arthritis: a population-based case-control study.
    Arthritis Res Ther. 2018;20:175.
    PubMed     Text format     Abstract available


  12. HASHIMOTO M, Furu M, Yamamoto W, Fujimura T, et al
    Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study.
    Arthritis Res Ther. 2018;20:165.
    PubMed     Text format     Abstract available


  13. NARASIMHAN R, Coras R, Rosenthal SB, Sweeney SR, et al
    Serum metabolomic profiling predicts synovial gene expression in rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:164.
    PubMed     Text format     Abstract available


  14. ISHII S, Isozaki T, Furuya H, Takeuchi H, et al
    ADAM-17 is expressed on rheumatoid arthritis fibroblast-like synoviocytes and regulates proinflammatory mediator expression and monocyte adhesion.
    Arthritis Res Ther. 2018;20:159.
    PubMed     Text format     Abstract available


    July 2018
  15. COHEN SB, Alten R, Kameda H, Hala T, et al
    A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.
    Arthritis Res Ther. 2018;20:155.
    PubMed     Text format     Abstract available


  16. ANGIOLILLI C, Kabala PA, Grabiec AM, Rossato M, et al
    Control of cytokine mRNA degradation by the histone deacetylase inhibitor ITF2357 in rheumatoid arthritis fibroblast-like synoviocytes: beyond transcriptional regulation.
    Arthritis Res Ther. 2018;20:148.
    PubMed     Text format     Abstract available


  17. ALDRIDGE J, Pandya JM, Meurs L, Andersson K, et al
    Sex-based differences in association between circulating T cell subsets and disease activity in untreated early rheumatoid arthritis patients.
    Arthritis Res Ther. 2018;20:150.
    PubMed     Text format     Abstract available


  18. TANAKA Y, Kameda H, Saito K, Kaneko Y, et al
    Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naive rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study.
    Arthritis Res Ther. 2018;20:151.
    PubMed     Text format     Abstract available


  19. JONSSON MK, Hensvold AH, Hansson M, Aga AB, et al
    The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy.
    Arthritis Res Ther. 2018;20:146.
    PubMed     Text format     Abstract available


  20. SERGEANT JC, Hyrich KL, Anderson J, Kopec-Harding K, et al
    Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS).
    Arthritis Res Ther. 2018;20:147.
    PubMed     Text format     Abstract available


    June 2018
  21. CHEN YL, Jing J, Mo YQ, Ma JD, et al
    Presence of hepatitis B virus in synovium and its clinical significance in rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:130.
    PubMed     Text format     Abstract available


  22. STRAND V, Gossec L, Proudfoot CWJ, Chen CI, et al
    Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:129.
    PubMed     Text format     Abstract available


  23. BARTLETT DB, Willis LH, Slentz CA, Hoselton A, et al
    Ten weeks of high-intensity interval walk training is associated with reduced disease activity and improved innate immune function in older adults with rheumatoid arthritis: a pilot study.
    Arthritis Res Ther. 2018;20:127.
    PubMed     Text format     Abstract available


  24. QIAN J, Xu L, Sun X, Wang Y, et al
    Correction to: Adiponectin aggravates bone erosion by promoting osteopontin production in synovial tissue of rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:125.
    PubMed     Text format     Abstract available


  25. CHANDRASEKHARAN UM, Wang Z, Wu Y, Wilson Tang WH, et al
    Elevated levels of plasma symmetric dimethylarginine and increased arginase activity as potential indicators of cardiovascular comorbidity in rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:123.
    PubMed     Text format     Abstract available


  26. RIVIERE E, Sellam J, Pascaud J, Ravaud P, et al
    Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:122.
    PubMed     Text format     Abstract available


    May 2018
  27. WEINBLATT ME
    Methotrexate: who would have predicted its importance in rheumatoid arthritis?
    Arthritis Res Ther. 2018;20:103.
    PubMed     Text format    


  28. RIFBJERG-MADSEN S, Christensen AW, Boesen M, Christensen R, et al
    The course of pain hypersensitivity according to painDETECT in patients with rheumatoid arthritis initiating treatment: results from the prospective FRAME-cohort study.
    Arthritis Res Ther. 2018;20:105.
    PubMed     Text format     Abstract available


  29. BALOGH E, Veale DJ, McGarry T, Orr C, et al
    Oxidative stress impairs energy metabolism in primary cells and synovial tissue of patients with rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:95.
    PubMed     Text format     Abstract available


  30. DRUCE KL, Aikman L, Dilleen M, Burden A, et al
    Fatigue independently predicts different work disability dimensions in etanercept-treated rheumatoid arthritis and ankylosing spondylitis patients.
    Arthritis Res Ther. 2018;20:96.
    PubMed     Text format     Abstract available


  31. BOETERS DM, Trouw LA, van der Helm-van Mil AHM, van Steenbergen HW, et al
    Does information on novel identified autoantibodies contribute to predicting the progression from undifferentiated arthritis to rheumatoid arthritis: a study on anti-CarP antibodies as an example.
    Arthritis Res Ther. 2018;20:94.
    PubMed     Text format     Abstract available


  32. RYDELL E, Forslind K, Nilsson JA, Jacobsson LTH, et al
    Smoking, body mass index, disease activity, and the risk of rapid radiographic progression in patients with early rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:82.
    PubMed     Text format     Abstract available


  33. ENGDAHL C, Bondt A, Harre U, Raufer J, et al
    Estrogen induces St6gal1 expression and increases IgG sialylation in mice and patients with rheumatoid arthritis: a potential explanation for the increased risk of rheumatoid arthritis in postmenopausal women.
    Arthritis Res Ther. 2018;20:84.
    PubMed     Text format     Abstract available


  34. COLE S, Walsh A, Yin X, Wechalekar MD, et al
    Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus.
    Arthritis Res Ther. 2018;20:85.
    PubMed     Text format     Abstract available


  35. KAN HJ, Dyagilev K, Schulam P, Saria S, et al
    Factors associated with physicians' prescriptions for rheumatoid arthritis drugs not filled by patients.
    Arthritis Res Ther. 2018;20:79.
    PubMed     Text format     Abstract available


  36. CHEN YL, Lin JZ, Mo YQ, Ma JD, et al
    Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study.
    Arthritis Res Ther. 2018;20:81.
    PubMed     Text format     Abstract available


    April 2018
  37. ZHOU YZ, Zhao LD, Chen H, Zhang Y, et al
    Comparison of the impact of Tripterygium wilfordii Hook F and Methotrexate treatment on radiological progression in active rheumatoid arthritis: 2-year follow up of a randomized, non-blinded, controlled study.
    Arthritis Res Ther. 2018;20:70.
    PubMed     Text format     Abstract available


  38. BURGERS LE, Boeters DM, Reijnierse M, van der Helm-van Mil AHM, et al
    Does the presence of magnetic resonance imaging-detected osteitis at diagnosis with rheumatoid arthritis lower the risk for achieving disease-modifying antirheumatic drug-free sustained remission: results of a longitudinal study.
    Arthritis Res Ther. 2018;20:68.
    PubMed     Text format     Abstract available


  39. KAWAGUCHI H, Matsumoto I, Osada A, Kurata I, et al
    Identification of novel biomarker as citrullinated inter-alpha-trypsin inhibitor heavy chain 4, specifically increased in sera with experimental and rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:66.
    PubMed     Text format     Abstract available


    March 2018
  40. MACHADO MAA, Moura CS, Guerra SF, Curtis JR, et al
    Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.
    Arthritis Res Ther. 2018;20:60.
    PubMed     Text format     Abstract available


  41. CAPPELLI LC, Konig MF, Gelber AC, Bingham CO 3rd, et al
    Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:59.
    PubMed     Text format     Abstract available


  42. GENOVESE M, Westhovens R, Meuleners L, Van der Aa A, et al
    Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes.
    Arthritis Res Ther. 2018;20:57.
    PubMed     Text format     Abstract available


  43. SUZUKI K, Yoshida K, Ueha T, Kaneshiro K, et al
    Methotrexate upregulates circadian transcriptional factors PAR bZIP to induce apoptosis on rheumatoid arthritis synovial fibroblasts.
    Arthritis Res Ther. 2018;20:55.
    PubMed     Text format     Abstract available


  44. MUELLER SM, Aguayo D, Aeberli D, Vogelin E, et al
    Myocellular characteristics in rheumatoid arthritis and osteoarthritis patients.
    Arthritis Res Ther. 2018;20:51.
    PubMed     Text format    


  45. BERGSTROM B, Carlsten H, Ekwall AH
    Methotrexate inhibits effects of platelet-derived growth factor and interleukin-1beta on rheumatoid arthritis fibroblast-like synoviocytes.
    Arthritis Res Ther. 2018;20:49.
    PubMed     Text format     Abstract available


  46. LOFGREN M, Opava CH, Demmelmaier I, Friden C, et al
    Pain sensitivity at rest and during muscle contraction in persons with rheumatoid arthritis: a substudy within the Physical Activity in Rheumatoid Arthritis 2010 study.
    Arthritis Res Ther. 2018;20:48.
    PubMed     Text format     Abstract available


  47. SCHWEDLER C, Haupl T, Kalus U, Blanchard V, et al
    Hypogalactosylation of immunoglobulin G in rheumatoid arthritis: relationship to HLA-DRB1 shared epitope, anticitrullinated protein antibodies, rheumatoid factor, and correlation with inflammatory activity.
    Arthritis Res Ther. 2018;20:44.
    PubMed     Text format     Abstract available


  48. WANG K, Zhang D, Liu Y, Wang X, et al
    Traditional Chinese medicine formula Bi-Qi capsule alleviates rheumatoid arthritis-induced inflammation, synovial hyperplasia, and cartilage destruction in rats.
    Arthritis Res Ther. 2018;20:43.
    PubMed     Text format     Abstract available


  49. TAKEUCHI T, Yamanaka H, Harigai M, Tamamura R, et al
    Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients.
    Arthritis Res Ther. 2018;20:42.
    PubMed     Text format     Abstract available


    February 2018
  50. HAHNLEIN JS, Nadafi R, de Jong T, Ramwadhdoebe TH, et al
    Impaired lymph node stromal cell function during the earliest phases of rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:35.
    PubMed     Text format     Abstract available


  51. DE MOEL EC, Derksen VFAM, Stoeken G, Trouw LA, et al
    Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes.
    Arthritis Res Ther. 2018;20:33.
    PubMed     Text format     Abstract available


  52. QIAN J, Xu L, Sun X, Wang Y, et al
    Adiponectin aggravates bone erosion by promoting osteopontin production in synovial tissue of rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:26.
    PubMed     Text format     Abstract available


    January 2018
  53. CHOWDHURY K, Kumar U, Das S, Chaudhuri J, et al
    Synovial IL-9 facilitates neutrophil survival, function and differentiation of Th17 cells in rheumatoid arthritis.
    Arthritis Res Ther. 2018;20:18.
    PubMed     Text format     Abstract available


  54. SMOLEN JS, Szumski A, Koenig AS, Jones TV, et al
    Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
    Arthritis Res Ther. 2018;20:8.
    PubMed     Text format     Abstract available


  55. HARROLD LR, Litman HJ, Saunders KC, Dandreo KJ, et al
    One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.
    Arthritis Res Ther. 2018;20:2.
    PubMed     Text format     Abstract available


    December 2017
  56. OUBOUSSAD L, Hunt L, Hensor EMA, Nam JL, et al
    Profiling microRNAs in individuals at risk of progression to rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:288.
    PubMed     Text format     Abstract available


  57. CHO SK, Lee J, Han M, Bae SC, et al
    The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs.
    Arthritis Res Ther. 2017;19:277.
    PubMed     Text format     Abstract available


  58. CURTIS JR, Winthrop K, O'Brien C, Ndlovu MN, et al
    Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment.
    Arthritis Res Ther. 2017;19:276.
    PubMed     Text format     Abstract available


  59. KUCA-WARNAWIN E, Kurowska W, Prochorec-Sobieszek M, Radzikowska A, et al
    Rheumatoid arthritis bone marrow environment supports Th17 response.
    Arthritis Res Ther. 2017;19:274.
    PubMed     Text format     Abstract available


  60. SATO H, Muraoka S, Kusunoki N, Masuoka S, et al
    Resistin upregulates chemokine production by fibroblast-like synoviocytes from patients with rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:263.
    PubMed     Text format     Abstract available


  61. LAI NS, Yu HC, Tung CH, Huang KY, et al
    The role of aberrant expression of T cell miRNAs affected by TNF-alpha in the immunopathogenesis of rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:261.
    PubMed     Text format     Abstract available


    November 2017
  62. BERGSTRA SA, Allaart CF, van den Berg R, Chopra A, et al
    Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:258.
    PubMed     Text format     Abstract available


  63. YANG X, Lin K, Ni S, Wang J, et al
    Serum connective tissue growth factor is a highly discriminatory biomarker for the diagnosis of rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:257.
    PubMed     Text format     Abstract available


  64. JIN S, Li M, Fang Y, Li Q, et al
    Chinese Registry of rheumatoid arthritis (CREDIT): II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:251.
    PubMed     Text format     Abstract available


  65. BLACK RJ, Lester S, Buchbinder R, Barrett C, et al
    Factors associated with oral glucocorticoid use in patients with rheumatoid arthritis: a drug use study from a prospective national biologics registry.
    Arthritis Res Ther. 2017;19:253.
    PubMed     Text format     Abstract available


  66. ZHOU L, Wang G, Liu X, Song J, et al
    Matrix metalloproteinase-3 and the 7-joint ultrasound score in the assessment of disease activity and therapeutic efficacy in patients with moderate to severe rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:250.
    PubMed     Text format     Abstract available


  67. ANAPARTI V, Smolik I, Meng X, Spicer V, et al
    Whole blood microRNA expression pattern differentiates patients with rheumatoid arthritis, their seropositive first-degree relatives, and healthy unrelated control subjects.
    Arthritis Res Ther. 2017;19:249.
    PubMed     Text format     Abstract available


    October 2017
  68. JOO YB, Kim Y, Park Y, Kim K, et al
    Biological function integrated prediction of severe radiographic progression in rheumatoid arthritis: a nested case control study.
    Arthritis Res Ther. 2017;19:244.
    PubMed     Text format     Abstract available


  69. ROMAO VC, Vital EM, Fonseca JE, Buch MH, et al
    Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?
    Arthritis Res Ther. 2017;19:239.
    PubMed     Text format     Abstract available


  70. MCQUEEN FM, Chapman P, Pollock T, D'Souza D, et al
    Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:241.
    PubMed     Text format     Abstract available


  71. MANDL T, Marsal J, Olsson P, Ohlsson B, et al
    Severe intestinal dysbiosis is prevalent in primary Sjogren's syndrome and is associated with systemic disease activity.
    Arthritis Res Ther. 2017;19:237.
    PubMed     Text format     Abstract available


  72. SAITO S, Suzuki K, Yoshimoto K, Kaneko Y, et al
    A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:231.
    PubMed     Text format     Abstract available


  73. TEJERA-SEGURA B, Lopez-Mejias R, Dominguez-Luis MJ, de Vera-Gonzalez AM, et al
    Incretins in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:229.
    PubMed     Text format     Abstract available


  74. SHIMIZU T, Choi HJ, Heilmeier U, Tanaka M, et al
    Assessment of 3-month changes in bone microstructure under anti-TNFalpha therapy in patients with rheumatoid arthritis using high-resolution peripheral quantitative computed tomography (HR-pQCT).
    Arthritis Res Ther. 2017;19:222.
    PubMed     Text format     Abstract available


  75. HAMMER HB, Kvien TK, Terslev L
    Ultrasound of the hand is sufficient to detect subclinical inflammation in rheumatoid arthritis remission: a post hoc longitudinal study.
    Arthritis Res Ther. 2017;19:221.
    PubMed     Text format     Abstract available


    September 2017
  76. BERGSTRA SA, Olivas O, Akdemir G, Riyazi N, et al
    Further Treatment Intensification in Undifferentiated and Rheumatoid Arthritis Patients Already in Low Disease Activity has Limited Benefit towards Physical Functioning.
    Arthritis Res Ther. 2017;19:220.
    PubMed     Text format     Abstract available


  77. SHERINA N, Hreggvidsdottir HS, Bengtsson C, Hansson M, et al
    Low levels of antibodies against common viruses associate with anti-citrullinated protein antibody-positive rheumatoid arthritis; implications for disease aetiology.
    Arthritis Res Ther. 2017;19:219.
    PubMed     Text format     Abstract available


  78. CURTIS JR, Herrem C, Ndlovu 'N, O'Brien C, et al
    A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial.
    Arthritis Res Ther. 2017;19:215.
    PubMed     Text format     Abstract available


  79. OLAH C, Kardos Z, Sepsi M, Sas A, et al
    Assessment of intracranial vessels in association with carotid atherosclerosis and brain vascular lesions in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:213.
    PubMed     Text format     Abstract available


  80. CHALLA DN, Kvrgic Z, Cheville AL, Crowson CS, et al
    Patient-provider discordance between global assessments of disease activity in rheumatoid arthritis: a comprehensive clinical evaluation.
    Arthritis Res Ther. 2017;19:212.
    PubMed     Text format     Abstract available


  81. SCHIFF M, Takeuchi T, Fleischmann R, Gaich CL, et al
    Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.
    Arthritis Res Ther. 2017;19:208.
    PubMed     Text format     Abstract available


  82. KABALA PA, Angiolilli C, Yeremenko N, Grabiec AM, et al
    Endoplasmic reticulum stress cooperates with Toll-like receptor ligation in driving activation of rheumatoid arthritis fibroblast-like synoviocytes.
    Arthritis Res Ther. 2017;19:207.
    PubMed     Text format     Abstract available


  83. TAKEUCHI T, Miyasaka N, Inui T, Yano T, et al
    High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the R
    Arthritis Res Ther. 2017;19:194.
    PubMed     Text format     Abstract available


  84. ZIEGELASCH M, Forslind K, Skogh T, Riklund K, et al
    Decrease in bone mineral density during three months after diagnosis of early rheumatoid arthritis measured by digital X-ray radiogrammetry predicts radiographic joint damage after one year.
    Arthritis Res Ther. 2017;19:195.
    PubMed     Text format     Abstract available


    August 2017
  85. SHAH NR, Noll BD, Stevens CB, Brennan MT, et al
    Biosemantics guided gene expression profiling of Sjogren's syndrome: a comparative analysis with systemic lupus erythematosus and rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:192.
    PubMed     Text format     Abstract available


  86. VAN DELFT MAM, Verheul MK, Burgers LE, Derksen VFAM, et al
    The isotype and IgG subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients.
    Arthritis Res Ther. 2017;19:190.
    PubMed     Text format     Abstract available


  87. NAKAGAWA J, Koyama Y, Kawakami A, Ueki Y, et al
    A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study.
    Arthritis Res Ther. 2017;19:185.
    PubMed     Text format     Abstract available


  88. LUNDSTROM SL, Hensvold AH, Rutishauser D, Klareskog L, et al
    IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:182.
    PubMed     Text format     Abstract available


    July 2017
  89. JAMSHIDI A, Gharibdoost F, Vojdanian M, Soroosh SG, et al
    A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA(R)) to the reference product (Humira(R)) in patients with active rheumat
    Arthritis Res Ther. 2017;19:168.
    PubMed     Text format     Abstract available


  90. TEITSMA XM, Jacobs JWG, Mokry M, Borm MEA, et al
    Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy.
    Arthritis Res Ther. 2017;19:170.
    PubMed     Text format     Abstract available


  91. MACLAUCHLAN S, Zuriaga MA, Fuster JJ, Cuda CM, et al
    Genetic deficiency of Wnt5a diminishes disease severity in a murine model of rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:166.
    PubMed     Text format     Abstract available


  92. BONDT A, Nicolardi S, Jansen BC, Kuijper TM, et al
    IgA N- and O-glycosylation profiling reveals no association with the pregnancy-related improvement in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:160.
    PubMed     Text format     Abstract available


  93. JIN Y, Desai RJ, Liu J, Choi NK, et al
    Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:159.
    PubMed     Text format     Abstract available


  94. SCHOELS M, Alasti F, Smolen JS, Aletaha D, et al
    Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition.
    Arthritis Res Ther. 2017;19:155.
    PubMed     Text format     Abstract available


  95. CASTANEDA S, Llorente I, Garcia-Vicuna R, Gonzalez-Alvaro I, et al
    Anti-citrullinated protein antibodies and bone loss in patients with early arthritis: comment on the article "Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untr
    Arthritis Res Ther. 2017;19:152.
    PubMed     Text format    


  96. OH BR, Suh DH, Bae D, Ha N, et al
    Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro.
    Arthritis Res Ther. 2017;19:154.
    PubMed     Text format     Abstract available


    June 2017
  97. KOKKONEN H, Stenlund H, Rantapaa-Dahlqvist S
    Cardiovascular risk factors predate the onset of symptoms of rheumatoid arthritis: a nested case-control study.
    Arthritis Res Ther. 2017;19:148.
    PubMed     Text format     Abstract available


  98. CABRERA-VILLALBA S, Gomara MJ, Canete JD, Ramirez J, et al
    Differing specificities and isotypes of anti-citrullinated peptide/protein antibodies in palindromic rheumatism and rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:141.
    PubMed     Text format     Abstract available


  99. SOLOMON DH, Shadick NA, Weinblatt ME, Zak A, et al
    Drug safety analyses in a rheumatoid arthritis registry: application of different approaches regarding timing of exposure and confounder measurement.
    Arthritis Res Ther. 2017;19:130.
    PubMed     Text format     Abstract available


  100. WANG J, Wen Y, Zhou M, Shi X, et al
    Ectopic germinal center and megalin defect in primary Sjogren syndrome with renal Fanconi syndrome.
    Arthritis Res Ther. 2017;19:120.
    PubMed     Text format     Abstract available


    May 2017
  101. TEJERA-SEGURA B, Macia-Diaz M, Machado JD, de Vera-Gonzalez A, et al
    HDL cholesterol efflux capacity in rheumatoid arthritis patients: contributing factors and relationship with subclinical atherosclerosis.
    Arthritis Res Ther. 2017;19:113.
    PubMed     Text format     Abstract available


  102. BOETERS DM, Mangnus L, Ajeganova S, Lindqvist E, et al
    The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical.
    Arthritis Res Ther. 2017;19:115.
    PubMed     Text format     Abstract available


  103. YOO J, Lee SK, Lim M, Sheen D, et al
    Exosomal amyloid A and lymphatic vessel endothelial hyaluronic acid receptor-1 proteins are associated with disease activity in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:119.
    PubMed     Text format     Abstract available


  104. BUSTAMANTE MF, Garcia-Carbonell R, Whisenant KD, Guma M, et al
    Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:110.
    PubMed     Text format     Abstract available


  105. SHODA H, Nagafuchi Y, Tsuchida Y, Sakurai K, et al
    Increased serum concentrations of IL-1 beta, IL-21 and Th17 cells in overweight patients with rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:111.
    PubMed     Text format     Abstract available


  106. CHANDRUPATLA DMSH, Jansen G, Vos R, Verlaan M, et al
    In-vivo monitoring of anti-folate therapy in arthritic rats using [(18)F]fluoro-PEG-folate and positron emission tomography.
    Arthritis Res Ther. 2017;19:114.
    PubMed     Text format     Abstract available


  107. ALDRICH MB, Velasquez FC, Kwon S, Azhdarinia A, et al
    Lymphatic delivery of etanercept via nanotopography improves response to collagen-induced arthritis.
    Arthritis Res Ther. 2017;19:116.
    PubMed     Text format     Abstract available


  108. KAWASHIRI SY, Fujikawa K, Nishino A, Okada A, et al
    Ultrasound-detected bone erosion is a relapse risk factor after discontinuation of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis whose ultrasound power Doppler synovitis activity and clinical disease activity are
    Arthritis Res Ther. 2017;19:108.
    PubMed     Text format     Abstract available


  109. GOIN DE, Smed MK, Pachter L, Purdom E, et al
    Pregnancy-induced gene expression changes in vivo among women with rheumatoid arthritis: a pilot study.
    Arthritis Res Ther. 2017;19:104.
    PubMed     Text format     Abstract available


  110. DERAMBURE C, Dzangue-Tchoupou G, Berard C, Vergne N, et al
    Pre-silencing of genes involved in the electron transport chain (ETC) pathway is associated with responsiveness to abatacept in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:109.
    PubMed     Text format     Abstract available


  111. PENATTI A, Facciotti F, De Matteis R, Larghi P, et al
    Differences in serum and synovial CD4+ T cells and cytokine profiles to stratify patients with inflammatory osteoarthritis and rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:103.
    PubMed     Text format     Abstract available


  112. THIEL J, Rizzi M, Engesser M, Dufner AK, et al
    B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.
    Arthritis Res Ther. 2017;19:101.
    PubMed     Text format     Abstract available


  113. NAKACHI S, Sumitomo S, Tsuchida Y, Tsuchiya H, et al
    Interleukin-10-producing LAG3+ regulatory T cells are associated with disease activity and abatacept treatment in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:97.
    PubMed     Text format     Abstract available


  114. GRABNER M, Boytsov NN, Huang Q, Zhang X, et al
    Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis.
    Arthritis Res Ther. 2017;19:92.
    PubMed     Text format     Abstract available


  115. STANDISH KA, Huang CC, Curran ME, Schork NJ, et al
    Comprehensive analysis of treatment response phenotypes in rheumatoid arthritis for pharmacogenetic studies.
    Arthritis Res Ther. 2017;19:90.
    PubMed     Text format     Abstract available


  116. SAUER BC, Teng CC, Accortt NA, Burningham Z, et al
    Models solely using claims-based administrative data are poor predictors of rheumatoid arthritis disease activity.
    Arthritis Res Ther. 2017;19:86.
    PubMed     Text format     Abstract available


  117. RYKOVA E, Sizikov A, Roggenbuck D, Antonenko O, et al
    Circulating DNA in rheumatoid arthritis: pathological changes and association with clinically used serological markers.
    Arthritis Res Ther. 2017;19:85.
    PubMed     Text format     Abstract available


    April 2017
  118. REED GW, Collier DH, Koenig AS, Saunders KC, et al
    Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:81.
    PubMed     Text format     Abstract available


  119. ISSA SF, Duer A, Ostergaard M, Horslev-Petersen K, et al
    Increased galectin-3 may serve as a serologic signature of pre-rheumatoid arthritis while markers of synovitis and cartilage do not differ between early undifferentiated arthritis subsets.
    Arthritis Res Ther. 2017;19:80.
    PubMed     Text format     Abstract available


  120. KUIJPER TM, Folmer R, Stolk EA, Hazes JMW, et al
    Doctors' preferences in de-escalating DMARDs in rheumatoid arthritis: a discrete choice experiment.
    Arthritis Res Ther. 2017;19:78.
    PubMed     Text format     Abstract available


  121. ANDRES CEREZO L, Sumova B, Prajzlerova K, Veigl D, et al
    Calgizzarin (S100A11): a novel inflammatory mediator associated with disease activity of rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:79.
    PubMed     Text format     Abstract available


  122. KUULIALA K, Kuuliala A, Koivuniemi R, Kautiainen H, et al
    Baseline JAK phosphorylation profile of peripheral blood leukocytes, studied by whole blood phosphospecific flow cytometry, is associated with 1-year treatment response in early rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:75.
    PubMed     Text format     Abstract available


  123. TAKAHASHI S, Saegusa J, Sendo S, Okano T, et al
    Glutaminase 1 plays a key role in the cell growth of fibroblast-like synoviocytes in rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:76.
    PubMed     Text format     Abstract available


  124. KILTZ U, von Zabern C, Baraliakos X, Heldmann F, et al
    Diagnostic value of a 3-day course of prednisolone in patients with possible rheumatoid arthritis - the TryCort study.
    Arthritis Res Ther. 2017;19:73.
    PubMed     Text format     Abstract available


    March 2017
  125. MENG W, Zhu Z, Jiang X, Too CL, et al
    DNA methylation mediates genotype and smoking interaction in the development of anti-citrullinated peptide antibody-positive rheumatoid arthritis.
    Arthritis Res Ther. 2017;19:71.
    PubMed     Text format     Abstract available


  126. ALBRECHT K, Zink A
    Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies.
    Arthritis Res Ther. 2017;19:68.
    PubMed     Text format     Abstract available


  127. JIANG J, Liu C, Liu M, Shen Y, et al
    OX40 signaling is involved in the autoactivation of CD4+CD28- T cells and contributes to the pathogenesis of autoimmune arthritis.
    Arthritis Res Ther. 2017;19:67.
    PubMed     Text format     Abstract available


  128. VAN DEN BRANDT S, Zbinden A, Baeten D, Villiger PM, et al
    Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients.
    Arthritis Res Ther. 2017;19:64.
    PubMed     Text format     Abstract available


  129. PERES RS, Santos GB, Cecilio NT, Jabor VA, et al
    Lapachol, a compound targeting pyrimidine metabolism, ameliorates experimental autoimmune arthritis.
    Arthritis Res Ther. 2017;19:47.
    PubMed     Text format     Abstract available


  130. CURTIS JR, Chen L, Higginbotham P, Nowell WB, et al
    Social media for arthritis-related comparative effectiveness and safety research and the impact of direct-to-consumer advertising.
    Arthritis Res Ther. 2017;19:48.
    PubMed     Text format     Abstract available


  131. OLSSON P, Turesson C, Mandl T, Jacobsson L, et al
    Cigarette smoking and the risk of primary Sjogren's syndrome: a nested case control study.
    Arthritis Res Ther. 2017;19:50.
    PubMed     Text format     Abstract available


    February 2017
  132. KLEYER A, Beyer L, Simon C, Stemmler F, et al
    Development of three-dimensional prints of arthritic joints for supporting patients' awareness to structural damage.
    Arthritis Res Ther. 2017;19:34.
    PubMed     Text format     Abstract available


  133. CROWLEY T, O'Neil JD, Adams H, Thomas AM, et al
    Priming in response to pro-inflammatory cytokines is a feature of adult synovial but not dermal fibroblasts.
    Arthritis Res Ther. 2017;19:35.
    PubMed     Text format     Abstract available


    January 2017
  134. AQRAWI LA, Galtung HK, Vestad B, Ovstebo R, et al
    Identification of potential saliva and tear biomarkers in primary Sjogren's syndrome, utilising the extraction of extracellular vesicles and proteomics analysis.
    Arthritis Res Ther. 2017;19:14.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Rheumatoid Arthritis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: